Anti-cancer therapeutic approaches that target the vascular endothelial growth factor (VEGF) or inhibit its receptors, VEGF-receptor (VEGFR) 1 and VEGFR2, have recently been developed [18–21]. Here, VEGFA is linked to cancer.